Biogen bets more on Isis technology for neurological drugs  Sept
9 Mon Sep 9, 2013 7:00am EDT   The deal is the fourth between
the companies in the last two years, and aims to use the
"antisense" technology invented by Isis to accelerate discovery
of drug targets for neurodegenerative diseases.    "This is a
more expansive collaboration in which we will work together over
the next several years to use the Isis technology to probe the
biology of a disease, develop drug targets and then potentially
take those molecules forward," Biogen Chief Executive Officer
George Scangos said in a telephone interview.     "With the
efficiency of antisense we believe we should have a drug moving
forward pretty much every year," he said.   He put the potential
value of the deal for Isis at "several billion dollars," noting
that royalty payments for any eventual antisense drugs would be
in the double digit percentages, with smaller payments for non-
antisense compounds.  Comments (0)   Sponsored Links